Full-Time

Senior Associate

Global Stock Plans

Posted on 8/23/2025

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Finance & Banking (1)
Required Skills
Word/Pages/Docs
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in Business, Finance, HR, or a related field is preferred.
  • 3+ years of experience in global stock plan administration or equity compensation.
  • Experience with domestic and global equity taxation.
  • Prior experience working on broker equity system platforms such as E*TRADE, Bank of America, or other global stock plan systems.
  • Work experience requiring the use of analytical skills, dedication to accuracy and attention to detail, use of automated data tools and interfaces, as well as the use of Microsoft Word, Excel, and Outlook in an office setting.
  • Demonstrated excellence in teamwork and interpersonal skills while functioning in a fast-paced, automation-focused environment.
Responsibilities
  • Day-to-day administration of global stock plans, for employees across various countries.
  • Ensure accurate and timely processing of equity transactions and maintain detailed records of stock plan participant data.
  • Work closely with third party stock plan administrators and local country HR and Payroll contacts to ensure timely regulatory reporting.
  • Act as a liaison with all levels of corporate, finance, compensation, tax, accounting, and payroll to ensure proper administration of equity plans.
  • Contribute to process improvements, automation initiatives, and developing solutions to establish superior methodologies.
  • Serve as the primary contact for employee questions globally regarding stock plan inquiries, grant details, tax implications, and other equity-related questions.
  • Support communication to employees regarding their stock plan grants, vesting schedules, exercise windows, and any changes to the programs.
  • Coordinate with equity vendor to provide educational sessions to help employees understand their benefits and the tax implications of their equity awards.
  • Ensure accuracy of participant data in equity management system.
  • Work closely with the HRIS team to ensure seamless integration between stock plan data and Amgen HRIS systems.
  • Ensure accurate recordkeeping and reconciliation of equity awards, including managing stock plan transactions (e.g., vesting, exercises, forfeitures) in a timely manner.
  • Maintain the policy and procedural documentation.
  • Prepare regular reports on stock plan participation, plan usage, and any other metrics requested by senior management or other departments.
  • Execute audit and SOX related control activities to ensure compliance and governance of global stock plans.
  • Assist in the preparation of compensation-related disclosures for financial reports and audits (e.g., 10-K, proxy statement).
  • Produce detailed analysis and preparation of standard and ad-hoc reports using appropriate tools and resources.
Desired Qualifications
  • Excellent communication skills, with the ability to work effectively with employees at all levels and in various regions.
  • Ability to effectively prioritize and balance multiple projects while meeting timelines and deliverables.
  • Ability to analyze data and translate insights into actionable program improvements.
  • Experience working in a large, diverse, global organization.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE